Psy156 - Quids In? – A Review of Whether Potential Blockbuster Savings From Biosimilar Adalimumab Should Be Reinvested in Other Disease Areas?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2730
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Unenumerated Rights: Whether and How Roe Should Be Overruled

University of Chicago Law Review
Law
1992English

Rare Disease Landscape: Will the Blockbuster Model Be Replaced?

Expert Opinion on Orphan Drugs
ToxicologyPharmaceuticsPharmacologyHealth Policy
2014English

Health Should Not Be a Determinative Factor of Whether One Will Be a Suitable Adoptive Parent

Indiana Health Law Review
2009English

Physicochemical and Functional Characterization of a Biosimilar Adalimumab ZRC-3197

Biosimilars
2014English

Flow Chart Helps in Deciding Whether School Occupational Therapy Services Should Be Continued

American Journal of Occupational Therapy
MedicineOccupational Therapy
1994English

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

AboutOpen
2019English

Chronic Phase of Chagas Disease: Why Should It Be Treated? A Comprehensive Review

Memorias do Instituto Oswaldo Cruz
MedicineMicrobiology
2011English

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Advances in Therapy
MedicinePharmacology
2019English

Book Review: Other Areas

Political Studies Review
SociologyInternational RelationsPolitical Science
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy